Clinical Trial Update: A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) [Phase 1]

View source ↗

Summary

Phase 1 study of mRNA-5671/V941 as monotherapy and in combination with pembrolizumab (V941-001) was terminated, with results posted on 2025-01-28. The trial tar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• mRNA-5671/V941 (mRNA-5671)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED | Results posted: 2025-01-28